Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
30. März 2022 08:00 ET
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
09. März 2022 16:01 ET
|
Prometheus Biosciences
- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis-Associated...
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
01. März 2022 08:30 ET
|
Prometheus Biosciences
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
07. Februar 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
12. Januar 2022 08:30 ET
|
Prometheus Biosciences
- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for...
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
05. Januar 2022 08:30 ET
|
Prometheus Biosciences
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
03. Januar 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
07. Dezember 2021 07:00 ET
|
Prometheus Biosciences
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1...
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
12. November 2021 08:00 ET
|
Prometheus Biosciences
- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in...
Prometheus Biosciences to Present at Upcoming Investor Conferences
02. November 2021 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...